What is small cell neuroendocrine carcinoma of the bladder?
Small cell neuroendocrine carcinoma of the bladder is a rare and fast-growing bladder cancer. Under the microscope, its cells are small, crowded and have very little cytoplasm. They look almost identical to small cell lung cancer, the best-known cancer of this type (Ismaili, 2011).
The word neuroendocrine refers to features the cells share with hormone-producing nerve-like cells. The cancer is also called small cell carcinoma of the bladder or, in older texts, oat cell carcinoma.
Most bladder cancers are urothelial carcinomas, which start in the lining of the bladder. Small cell carcinoma makes up only a small fraction of bladder cancers, but it behaves much more aggressively. It tends to grow deeply into the bladder wall and to spread early to lymph nodes, liver, bones and lungs. Many people are diagnosed at an advanced stage (Ismaili, 2011).
The cancer is often found mixed with ordinary urothelial carcinoma in the same tumour. Genetic studies suggest that both may come from the same original cell, with the small cell part developing from a pre-existing urothelial cancer (Wang et al., 2019).
Treatment borrows from both small cell lung cancer and bladder cancer care. For disease confined to the bladder, the most effective approach is usually chemotherapy first, followed by removal of the bladder (radical cystectomy). Radiotherapy with chemotherapy is an alternative for people who cannot have surgery.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | High-grade neuroendocrine carcinoma of the bladder |
| How common | Rare; a small fraction of all bladder cancers |
| Who is affected | Mostly men in their 60s and 70s |
| Main symptom | Visible blood in the urine |
| Appearance | Indistinguishable from small cell lung cancer under the microscope |
| Mixed tumours | Often found together with urothelial carcinoma |
| Main treatment | Platinum-based chemotherapy, then cystectomy or radiotherapy |
| Spread | Early to lymph nodes and distant organs |
| Outlook | Poor overall; better when found early and treated with combined therapy |
2. Types
| Type | Description | Notes |
|---|---|---|
| Pure small cell carcinoma | Only small cell cancer present | Generally poorer outlook (Ismaili, 2011) |
| Mixed small cell carcinoma | Small cell cancer together with urothelial carcinoma or another type | Common; treated as small cell cancer |
| Large cell neuroendocrine carcinoma | A related, even rarer high-grade tumour | Treated in a similar way |
How it differs from ordinary bladder cancer
| Feature | Small cell carcinoma | Urothelial carcinoma |
|---|---|---|
| Frequency | Rare | The most common bladder cancer |
| Growth rate | Very fast | Usually slower |
| Depth at diagnosis | Usually muscle-invasive or beyond | Often superficial |
| Early spread | Common | Less common |
| First treatment for localised disease | Chemotherapy before surgery | Surgery, sometimes with chemotherapy |
| Chemotherapy regimens | Small cell regimens (etoposide with a platinum) | Urothelial regimens (for example gemcitabine with cisplatin) |
Is it lung cancer that has spread?
Because the cells look the same as small cell lung cancer, doctors will check the lungs with a CT scan. The diagnosis of bladder small cell carcinoma is made when the bladder is the main site, often supported by an accompanying urothelial component.
3. Causes and risk factors
| Risk factor | Notes |
|---|---|
| Smoking | The main risk factor for bladder cancer in general |
| Male sex | More common in men (Erdem et al., 2016) |
| Older age | Usually seventh and eighth decades |
| Chemical exposure at work | Dyes, rubber and some industrial chemicals raise bladder cancer risk |
| Existing urothelial cancer | The small cell component may develop from it |
Where does the cancer come from?
| Theory | Explanation |
|---|---|
| Common clone with urothelial carcinoma | Shared genetic changes suggest both arise from the same cell (Wang et al., 2019) |
| Multipotent stem cell | An immature cell that can develop in different directions (Ismaili, 2011) |
| Neuroendocrine cells in the bladder lining | Earlier theory, now considered less likely |
4. How does it look
On cystoscopy and scans
| Test | Typical findings |
|---|---|
| Cystoscopy | A large, solid, sometimes ulcerated tumour, often on the side walls or base |
| CT urogram | Bladder mass, thickened wall, enlarged lymph nodes |
| MRI of the pelvis | Depth of invasion |
| CT of the chest and abdomen | Spread to lungs, liver or nodes; excludes a lung primary |
| PET-CT | Detects spread not seen on CT |
| Bone scan or brain MRI | If symptoms suggest spread |
Under the microscope
| Feature | Description |
|---|---|
| Cells | Small, round or oval, with very little cytoplasm |
| Nuclei | Finely granular (“salt and pepper”) chromatin; nuclei mould against each other |
| Activity | Many dividing cells and areas of dead tissue |
| Neuroendocrine markers | Synaptophysin, chromogranin, CD56 or INSM1 often positive |
| Proliferation (Ki-67) | Very high |
Diagnosis follows the same WHO criteria used for small cell lung cancer (Erdem et al., 2016). Even if neuroendocrine stains are negative, the typical appearance is enough.
5. Symptoms
Common symptoms
- Blood in the urine (haematuria), usually visible, the most frequent symptom (Erdem et al., 2016)
- Passing urine more often or urgently
- Pain or burning when passing urine
Less common symptoms
| Symptom | Possible cause |
|---|---|
| Pelvic or back pain | Local spread or swollen nodes |
| Swollen legs | Pressure on veins or lymph channels |
| Bone pain | Spread to bone |
| Weight loss and tiredness | Advanced disease |
| Headaches or confusion | Spread to the brain |
| Hormone-related symptoms | Rarely, the tumour makes hormones, causing low sodium or high calcium |
When to seek medical advice
Blood in the urine should always be checked by a doctor, even if it happens only once and there is no pain. Most causes are not cancer, but bladder cancer needs to be excluded.
6. Diagnosis
| Test | Purpose |
|---|---|
| Urine tests | Exclude infection; look for abnormal cells |
| Flexible cystoscopy | Views the bladder lining |
| Transurethral resection of bladder tumour (TURBT) | Removes tumour tissue for diagnosis and shows how deep it goes |
| CT of chest, abdomen and pelvis | Staging and excludes a lung primary |
| MRI of the pelvis | Local extent |
| PET-CT | Distant spread |
| Brain MRI | Considered because small cell cancers can spread to the brain |
| Kidney function and blood tests | Fitness for cisplatin |
Staging
The cancer is staged with the TNM system used for urothelial bladder cancer (Ismaili, 2011). Doctors also group cases in the way used for small cell lung cancer.
| Group | Meaning | Typical treatment |
|---|---|---|
| Limited (localised) disease | Confined to the bladder and nearby tissue, possibly with nearby nodes | Chemotherapy, then cystectomy or chemoradiotherapy |
| Extensive (metastatic) disease | Spread beyond the pelvis or to distant organs | Chemotherapy, sometimes with immunotherapy |
7. Treatment
There are no randomised trials in this disease. Treatment is based on retrospective studies and on experience with small cell lung cancer (Erdem et al., 2016). Care should be planned by a multidisciplinary team experienced in bladder and neuroendocrine cancers.
Disease that can be removed
| Step | Details |
|---|---|
| Neoadjuvant chemotherapy | Usually four cycles of a platinum drug with etoposide |
| Radical cystectomy | Removal of the bladder and nearby lymph nodes, with a new way of passing urine |
| Further chemotherapy | Sometimes given after surgery if not given before |
Four cycles of chemotherapy followed by cystectomy is regarded as the most effective sequence for resectable disease (Ismaili, 2011). Surgery alone is not enough, because hidden spread is common (Erdem et al., 2016).
In a 20-year single-centre review of 38 patients, no single treatment was clearly superior in statistical terms. However, most long-term survivors had received platinum chemotherapy followed by cystectomy, and almost half of those given chemotherapy first had their tumour downstaged (Jung et al., 2017).
When surgery is not suitable
| Option | Notes |
|---|---|
| Chemoradiotherapy | Chemotherapy combined with radiotherapy to the bladder; preserves the bladder |
| Radiotherapy alone | For less fit patients |
| Prophylactic brain radiotherapy | Sometimes discussed, as in small cell lung cancer |
Advanced disease
| Treatment | Notes |
|---|---|
| Cisplatin or carboplatin with etoposide | Standard first treatment |
| Immunotherapy | Drugs such as atezolizumab or durvalumab are used with chemotherapy in small cell lung cancer and are sometimes extended to bladder cases |
| Second-line chemotherapy | For example topotecan or other regimens |
| Palliative radiotherapy | Controls bleeding or pain |
| Clinical trials | Including new targeted drugs such as those directed at DLL3 |
Side effects
| Treatment | Possible side effects |
|---|---|
| Platinum and etoposide chemotherapy | Low blood counts, infection, tiredness, hair loss, nausea, hearing and kidney effects with cisplatin |
| Radical cystectomy | Wound and urinary problems, changes in sexual function, need for a stoma or new bladder |
| Radiotherapy to the bladder | Frequent urination, bowel irritation, tiredness |
| Immunotherapy | Inflammation of organs such as bowel, lungs, liver or glands |
Living with a urinary diversion
| Type | What it means |
|---|---|
| Ileal conduit | Urine drains through a stoma into a bag on the abdomen |
| Neobladder | A new bladder made from bowel, emptied by passing urine normally |
| Continent pouch | An internal pouch emptied with a catheter |
Recovery after cystectomy
| Period | What to expect |
|---|---|
| Hospital stay | Usually 5-10 days |
| First 6 weeks | Gradual return to walking and light activity; no heavy lifting |
| 2-3 months | Most people return to many normal activities |
| Longer term | Adjusting to the stoma or neobladder, with specialist nurse support |
8. Outlook (prognosis)
| Factor | Effect |
|---|---|
| Stage at diagnosis | The most important factor (Erdem et al., 2016) |
| Pure small cell histology | Poorer than mixed tumours |
| Chemotherapy followed by cystectomy | Linked with the best long-term results |
| Spread to distant organs | Poor outlook |
In the Fox Chase review, median survival was just under 12 months, and around 1 in 7 patients were alive at five years (Jung et al., 2017). People with early-stage disease who complete combined treatment can achieve long survival.
Survival in the Fox Chase series
| Time | Overall survival |
|---|---|
| 1 year | About 47% |
| 3 years | About 26% |
| 5 years | About 14% |
9. Follow-up
| Time | Typical follow-up |
|---|---|
| First 2 years | Review and CT scans every 3 months |
| Years 3-5 | Every 6 months |
| If the bladder is kept | Regular cystoscopy |
| New symptoms | Brain MRI or other scans as needed |
| Long term | Kidney function, vitamin B12 and stoma care checks |
Better molecular understanding of this cancer may help to improve follow-up and treatment in future (Wang et al., 2019).
10. Living with small cell bladder cancer
- Stop smoking; your team can help with medicines and support
- Report fever promptly during chemotherapy
- Drink plenty of fluids unless told otherwise
- Learn stoma care with a specialist nurse if you have a urinary diversion
- Ask about sexual function after surgery; treatments and aids are available
- Keep active with regular walks, which help recovery and energy levels
- Carry a list of your treatments in case you need urgent care elsewhere
- Seek support from bladder cancer charities and stoma support groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it lung cancer? | No, it starts in the bladder, although it looks the same under the microscope |
| Why chemotherapy before surgery? | It treats hidden spread early and may shrink the tumour |
| Can I keep my bladder? | Chemoradiotherapy may be an option in some cases |
| Is it caused by smoking? | Smoking is the main risk factor for bladder cancer generally |
| Will I need a stoma? | Possibly, after cystectomy; some people can have a neobladder |
| How long does chemotherapy take? | Four cycles usually take about three months |
| Can it be cured? | Yes, in some people with early disease treated with combined therapy |
| Is it inherited? | No |
| Will I lose my hair? | Often, with etoposide-based chemotherapy, but it grows back |
12. Questions to ask your care team
- Is my cancer pure or mixed small cell carcinoma?
- Has it spread beyond the bladder?
- Do you recommend chemotherapy before surgery?
- Is bladder-preserving treatment possible for me?
- What type of urinary diversion would suit me?
- Do I need a brain scan?
- Are there any clinical trials I could join?
- What support is there for adjusting to life after treatment?
Resources
- Erdem, G.U. et al. (2016) ‘Small cell carcinoma of the urinary bladder: changing trends in the current literature’, Current Medical Research and Opinion, 32(6), pp. 1013-1021.
- Ismaili, N. (2011) ‘A rare bladder cancer – small cell carcinoma: review and update’, Orphanet Journal of Rare Diseases, 6, 75.
- Jung, K. et al. (2017) ‘Small-cell carcinoma of the bladder: 20-year single-institution retrospective review’, Clinical Genitourinary Cancer, 15(3), pp. e337-e343.
- Wang, Y. et al. (2019) ‘Small cell carcinoma of the bladder: the characteristics of molecular alterations, treatment, and follow-up’, Medical Oncology, 36(12), 98.
- National Cancer Institute (2026) Bladder Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.